Request Sample Inquiry
Europe Pharmaceutical Excipients Market

Europe Pharmaceutical Excipients Market

Europe Pharmaceutical Excipients Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

250

Base Year:

2023

Date

Oct - 2024

Format:

PDF XLS PPT

Report Code:

VMR-2976

Segments Covered
  • By Offerings By Offerings Organic Chemicals, Inorganic Chemicals
  • By End User By End User Oral Formulations, Liquid Formulations, Topical Formulations, Parenteral Formulations, Others
Snapshot
Base YearBase Year: 2023
Forecast YearsForecast Years: 2024 - 2032
Historical YearsHistorical Years: 2018 - 2022
Revenue 2023Revenue 2023: USD 2519.42 Million
Revenue 2032Revenue 2032: USD 4505.32 Million
Revenue CAGRRevenue CAGR (2024 - 2032): 6.6%
Fastest Growing Region Fastest Growing Region (2024 - 2032) XX
Largest Region Largest Region (2023): XX
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
Europe Pharmaceutical Excipients Market Share

The global Europe Pharmaceutical Excipients Market is valued at USD 2519.42 Million in 2023 and is projected to reach a value of USD 4505.32 Million by 2032 at a CAGR (Compound Annual Growth Rate) of 6.6% between 2024 and 2032. The market is driven by rising demand for generic drugs and advancements in drug formulations.

Key Highlights

  • In 2023, Western Europe dominated the market with 73.1% market share
  • By Offering, the Organic chemicals is dominated the market with 69.9% market share in 2023
  • Based on End User, the Oral formulation is dominated the market with 41.01% market share

Europe Pharmaceutical Excipients Market Size, 2023 To 2032 (USD Million)

AI (GPT) is here !!! Ask questions about Europe Pharmaceutical Excipients Market
Loading....

Offering Overview

The Offering Segment is divided into Organic chemicals and Inorganic chemicals. Organic chemicals is divided into Oleochemicals, Carbohydrate, and Petrochemicals. The Organic Chemicals held the dominant share in 2023, accounting for significant market share of 69.9%.

The wide range of carbon-based compounds used to enhance drug formulations are categorized as organic chemicals. Growing need for drug delivery systems, such as controlled-release and targeted delivery formulations, is fueling the rise of organic chemicals. The increasing incidence of chronic illnesses and the trend toward personalized therapy, that calls for increasingly advanced excipient solutions, lend credence to this.

End User Overview

The End User Segment is divided into Oral formulation, Liquid formulation, Topical formulation, Parenteral formulation, and others. The Oral formulation held the dominant share in 2023, accounting for significant market share of 41.01%.

Oral formulation is growing due to the convenience, efficient dosage forms and patient compliance associated with oral administration. Because of its cost-effectiveness, patient compliance, and convenience, the market is expanding rapidly. Because of their established use and convenience of administration, oral formulations such as tablets and capsules dominate the market.

Regional Overview

Europe Europe Pharmaceutical Excipients market is driven by advancements in drug development, increasing prevalence of chronic diseases, and a growing emphasis on personalized medicine. Through controlled-release formulations and innovative drug delivery methods, excipients can be used to improve patient compliance as well as drug stability and bioavailability.

The Western Europe held the largest market share and is anticipated to register the highest CAGR during the forecast period. The market is driven by an aging population, increasing prevalence of chronic diseases, technological advancement in drug delivery systems, growth in the generics market, and stringent regulatory requirement for drug quality and safety. For instance, BASF SE, a German chemical company, launched Kollicoat MAE 100-55 in 2020, a new excipient for enteric coating application. The company is also invested USD 150 Million in its Ludwigshafen site to expand pharmaceutical production capacity, demonstrating its commitment to the growing market.

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

  • Real-Time Data Updates:
  • Competitor Benchmarking
  • Market Trends Heatmap
  • Custom Research Queries
  • Market Sentiment Analysis
  • Demographic and Geographic Insights

Get Access Now

In Germany, Europe Pharmaceutical Excipients market is experiencing notable growth, driven by its robust pharmaceutical industry and strong focus on research and innovation. As Europe's largest economy and a leading pharmaceutical producer, Germany plays a crucial role in the continent's excipients market. The German Association for Pharmaceutical Science and Technology (APV) reports that excipients represent about 10-15% of the total cost of drug production, highlighting their economic importance.

Key Trends

  1. Increasing use of multifunctional excipients: Multifunctional excipients are becoming integral in modern drug formulations due to their ability to improve solubility, bioavailability, and drug absorption. With the pharmaceutical industry increasingly focusing on more complex drugs, especially those with poor solubility and stability issues, multifunctional excipients offer a streamlined solution
  2. Advances in drug delivery systems for biologics and biosimilars: The increasing demand for biologics and biosimilars, which have more complex molecular structures compared to small-molecule drugs, has brought about a need for specialized excipients
  3. Personalized medicine and customized excipients: The rise of personalized medicine, where treatments are tailored to individual genetic profiles or specific medical conditions, has significantly impacted the excipient market

{dashboard_image}}

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Increasing demand for personalized medicine

The shift towards personalized medicine represents a transformative trend in healthcare, significantly impacting the pharmaceuticals excipients market. Personalized medicine aims to tailor drug treatments to individual patient characteristics, such as genetic profiles, lifestyle, and disease specifics, to enhance therapeutic outcomes. This approach necessitates the use of specialized excipients that can support complex drug formulation and ensure optimal delivery and efficacy. Moreover, the rise of gene therapies and RNA-based treatments further exemplifies the need for specialized excipients. These therapies often utilize advanced delivery mechanism to transport therapeutic agents into cells, requiring excipients that ensure efficient encapsulation and release of genetic materials. The growing prevalence of such innovative treatments underscore the critical role of excipients in personalized medicine, driving continued research and investments in this fields.

Advancement in Drug Delivery Technologies

The rapid advancement in drug delivery technology is opening significant opportunities for pharmaceuticals excipient manufactures. Innovation such as controlled release formulations, transdermal patches, and nanomedicine are transforming how drugs are administered and manage, creating a demand for specialized excipients that can support these cutting-edge systems.

Competitive Landscape

The Europe Pharmaceutical Excipients market is characterized by dynamic and evolving environment with several key players and their ongoing advancement. Major Players are Ashland global holdings, BASF SE, DuPont, Evonik Industries AG, Archer Daniels Midland Company, Lubrizol Corporation, Croda International, Kerry Group, Roquette Freres, Merck KGaA, and other companies. These companies focus on product innovations, mergers, and partnerships to enhance their market presence. Increasing R&D investment and the development of advanced excipients to improve drug formulations are key strategies.

Recent Market Developments

Merck KGaA invested over €300 million in a new Life Science Research Center in Germany

  • In April 2024, Merck KGaA invested over €300 million in a new Life Science Research Center in Germany, aimed at accelerating biopharmaceutical product development. This advanced facility will unite research efforts across key technologies, fostering innovation and collaboration in the biopharmaceutical sector. The center is designed to enhance capabilities in drug discovery, development, and production, leveraging cutting-edge technologies to streamline and accelerate the path from research to market. This investment underscores Merck's commitment to advancing life sciences and improving global health outcomes through accelerated innovation

IFF and BASF's Pharma Solutions divisions have partnered to integrate IFF's top pharmaceutical excipient brands

  • In November 2023, IFF and BASF's Pharma Solutions divisions have partnered to integrate IFF's top pharmaceutical excipient brands into BASF's ZoomLab, a virtual pharma assistant platform. This science-driven digital tool helps pharmaceutical developers quickly and accurately select the ideal excipients for new formulations. ZoomLab simplifies the process of overcoming formulation challenges by predicting the best excipient combinations, streamlining drug development. The collaboration enhances the platform’s capabilities, offering more robust excipient options and improving formulation efficiency for pharmaceutical companies

The global Europe Pharmaceutical Excipients market can be categorized as Offering, End User and Region.

Parameter Details
Segments Covered

By Offerings

  • Organic Chemicals
    • Oleochemicals
      • Fatty Alcohols
      • Mineral Stearates
      • Glycerin
      • Other Oleochemicals
    • Carbohydrates
      • Sugars
      • Cellulose
      • Starch
    • Petrochemicals
      • Glycols
      • Povidones
      • Mineral Hydrocarbons
      • Acrylic Polymers
      • Others
  • Inorganic Chemicals
    • Calcium Phosphate
    • Metal Oxides
    • Halites
    • Calcium Carbonate
    • Calcium Sulphate
    • Other Chemicals

By End User

  • Oral Formulations
  • Liquid Formulations
  • Topical Formulations
  • Parenteral Formulations
  • Others

Regions & Countries Covered
  • North America - (U.S., Canada, Mexico)
  • Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
  • Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
  • Latin America - (Brazil, Argentina, Rest Of Latin America)
  • Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
Companies Covered
  • Ashland global holdings
  • BASF SE
  • DuPont
  • Evonik Industries AG
  • Archer Daniels Midland Company
  • Lubrizol Corporation
  • Croda International
  • Kerry Group
  • Roquette Freres
  • Merck KGaA
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis
Pricing and purchase options Avail of customized purchase options to meet your exact research needs. Explore purchase options

FAQ
Frequently Asked Question
  • The global Europe Pharmaceutical Excipients valued at USD 2519.42 Million in 2023 and is expected to reach USD 4505.32 Million in 2032 growing at a CAGR of 6.6%.

  • The prominent players in the market are Ashland global holdings, BASF SE, DuPont, Evonik Industries AG, Archer Daniels Midland Company, Lubrizol Corporation, Croda International, Kerry Group, Roquette Freres, Merck KGaA.

  • The market is project to grow at a CAGR of 6.6% between 2024 and 2032.

  • The driving factors of the Europe Pharmaceutical Excipients include

    • Increasing demand for personalized medicine

  • XX was the leading regional segment of the Europe Pharmaceutical Excipients in 2023.